BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity

Graphical Abstract

Highlights
- BCG vaccination of humans induces genome-wide epigenetic reprogramming in monocytes
- BCG-induced changes correlate with protection against experimental virus infection
- Viremia reduction correlates with IL-1β upregulation, indicative of trained immunity
- SNPs in IL1B affect the induction of trained immunity by BCG

Authors
Rob J.W. Arts, Simone J.C.F.M. Moorlag, Boris Novakovic, ..., Hendrik G. Stunnenberg, Reinout van Crevel, Mihai G. Netea

Correspondence
mihai.netea@radboudumc.nl

In Brief
In this paper, Arts et al. describe that BCG vaccination induces genome-wide epigenetic reprogramming of human monocytes that correlates with protection against experimental viral infection. Reduction of viremia correlated with upregulation of non-specific IL-1β production, and genetic polymorphisms in the IL-1 pathway affect the induction of trained immunity by BCG.

Data Resources
GSE104149

Arts et al., 2018, Cell Host & Microbe 23, 89–100
January 10, 2018 © 2017 Elsevier Inc.
https://doi.org/10.1016/j.chom.2017.12.010
BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity

Rob J.W. Arts,1,10 Simone J.C.F.M. Moorlag,1,10 Boris Novakovic,2 Yang Li,3 Shuang-Yin Wang,1 Marije Oosting,1 Vinod Kumar,3 Ramnik J. Xavier,4,5 Cisca Wijmenga,3 Leo A.B. Joosten,1 Chantal B.E.M. Reusken,6 Christine S. Benn,7,8 Peter Aaby,7,10 Marion P. Koopmans,6 Hendrik G. Stunnenberg,2 Reinout van Crevel,1 and Mihai G. Netea1,9,11,*

1Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands
2Department of Molecular Biology, Radboud University, Nijmegen, the Netherlands
3Department of Genetics, University Medical Center Groningen, Groningen, the Netherlands
4Center for Computational and Integrative Biology and Gastrointestinal Unit, Massachusetts General Hospital, Harvard School of Medicine, Boston, MA, USA
5Broad Institute of MIT and Harvard University, Cambridge, MA, USA
6Department Viroscience, WHO Collaborating Centre for Arboviruses and Viral Hemorrhagic Fever Reference and Research, Erasmus University Medical Center, Rotterdam, the Netherlands
7Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, Copenhagen, Denmark
8OPEN, Institute of Clinical Research, University of Southern Denmark/Odense University Hospital, Odense, Denmark
9Department for Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, 53115 Bonn, Germany
10These authors contributed equally
11Lead Contact
*Correspondence: mihai.netea@radboudumc.nl
https://doi.org/10.1016/j.chom.2017.12.010

SUMMARY

The tuberculosis vaccine bacillus Calmette-Guérin (BCG) has heterologous beneficial effects against non-related infections. The basis of these effects has been poorly explored in humans. In a randomized placebo-controlled human challenge study, we found that BCG vaccination induced genome-wide epigenetic reprogramming of monocytes and protected against experimental infection with an attenuated yellow fever virus vaccine strain. Epigenetic reprogramming was accompanied by functional changes indicative of trained immunity. Reduction of viremia was highly correlated with the upregulation of IL-1β, a heterologous cytokine associated with the induction of trained immunity, but not with the specific IFNγ response. The importance of IL-1β for the induction of trained immunity was validated through genetic, epigenetic, and immunological studies. In conclusion, BCG induces epigenetic reprogramming in human monocytes in vivo, followed by functional reprogramming and protection against non-related viral infections, with a key role for IL-1β as a mediator of trained immunity responses.

INTRODUCTION

Bacillus Calmette-Guérin (BCG) is a live-attenuated vaccine strain of Mycobacterium bovis that protects against mycobacterial infections such as tuberculosis and leprosy and has now been used for almost a century (Colditz et al., 1994; Zumla et al., 2013). Interestingly, the BCG vaccine also has heterologous protective effects against non-related infections: several epidemiological studies have shown that vaccination at birth results in reduced child mortality (Hirve et al., 2012; Kristensen et al., 2000; Moulton et al., 2005; Roth et al., 2003). These beneficial effects of BCG have been validated in randomized controlled trials, and the reduced mortality appeared to be mainly due to protection against neonatal sepsis and respiratory infections (Aaby et al., 2011; Biering-Sorensen et al., 2012; Roth et al., 2004). BCG vaccination has been also shown to protect against mortality in murine experimental models of non-mycobacterial infections (summarized in Blok et al., 2015). Lastly, BCG is used as non-specific immunotherapy in cancer, with BCG installations in bladder cancer inducing immune-stimulating effects that slow tumor progression (Han and Pan, 2006).

Two types of immunological mechanisms have been suggested to mediate these effects. First, CD4 and CD8 memory cells can be activated in an antigen-independent manner (e.g., by cytokines stimulated by a secondary infection), a process called heterologous immunity (Berg et al., 2002, 2003; Lertme-mongkolchai et al., 2001; Mathurin et al., 2009). Second, BCG vaccination induces histone modifications and epigenetic reprogramming of human monocytes at the promoter sites of genes encoding for inflammatory cytokines such as TNFA and IL6, resulting in a more active innate immune response upon restimulation, a process called trained immunity (Kleinnijenhuis et al., 2012; Netea et al., 2016). However, the extent of the effects of BCG on histone modifications at a genome-wide level remains unknown. Moreover, while the described epidemiological studies clearly suggest protective heterologous effects of BCG, controlled experimental studies in humans to establish the immunological basis for these observations remain unknown.
Figure 1. BCG Vaccination Induced Genome-wide H3K27ac Changes in Monocytes

(A–D) Monocytes from seven donors were analyzed by ChIP-seq to determine the distribution of H3K27ac at “baseline” (before BCG vaccination, −28d) and “BCG 1 month” (1 month after BCG vaccination, 0d).

(legend continued on next page)
outstanding, and the potential role of trained immunity in mediating these effects has not been assessed.

In this study, we examined the effects of BCG vaccination on genome-wide histone modifications induced in circulating monocytes by BCG vaccination. Subsequently, we examined the functional changes induced by BCG in monocytes and examined how BCG vaccination impacts viral, serological, and immunological parameters after yellow fever vaccine (YFV) administration. YFV is an attenuated viral strain that can be detected in the circulation after vaccination, thereby being an ideal model of experimental viral infection in humans. We show that BCG vaccination reduces the level of YFV viremia after vaccination and that this effect correlates with induction of cytokine responses indicative of trained immunity, with a crucial role for IL-1β production and release.

RESULTS

BCG Vaccination Induces Genome-wide Epigenetic Reprogramming of Human Monocytes In Vivo

In vitro experiments have previously shown that the increased cytokine responses after monocyte montage with BCG are the result of epigenetic changes (Arts et al., 2015). In order to examine the genome-wide rewiring of the epigenetic program by BCG, monocytes from seven donors were analyzed by chromatin immunoprecipitation sequencing (ChIP-seq) to determine genome-wide changes in the distribution of histone H3 acetylation at lysine 27 (H3K27ac), a marker of active promoters and enhancers, at “baseline” (before BCG vaccination, day −28) and “BCG 1 month” (1 month after BCG vaccination, day 0). Correlation plots of whole-genome H3K27ac sequencing reads showed a clear separation of the baseline and BCG samples, especially when analysis was limited to peaks that were highly induced (> 3 SD) in at least one donor or with a statistical significance when analysis was restricted to peaks related to promoters (Figures S1B and S1C). Finally, pathway analysis including genes near the 646 differential H3K27ac peaks (Figure 1B). A similar effect was seen when analysis was restricted to peaks related to promoters (Figures S1B and S1C). Finally, pathway analysis including genes near the 646 differential peaks showed differential regulation of several important signaling- and inflammatory-related pathways (Figure 1C; Tables S2 and S3).

Most changes induced by BCG vaccination in promoter regions involve G protein-coupled receptors and protein kinases, indicating the extensive effect of BCG on remodeling signal transduction molecules (Table S3). Accordingly, BCG induces increased H3K27ac in several important signaling pathways, including the PI3K/AKT (phosphatidylinositol 3-kinase) pathway, epidermal growth factor receptor (EGFR), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF) signaling pathways (Table S3) (upregulated genes involved in these pathways can be found in Table S4). Interestingly, genes such as AKT1, MAPKs, and PI3K-related genes that have been shown to be major regulators in β-glucan-induced trained immunity appear to be also important in BCG-induced trained immunity (Cheng et al., 2014; Saeed et al., 2014) (Figure 1D; Table S4). Genes directly involved in the inflammatory response and cytokine production also showed increased H3K27ac upon BCG vaccination. Intriguingly, the receptor of oxidized low-density lipoprotein (oxLDL), OLR1, a marker of atherosclerosis, previously shown to induce a long-term pro-inflammatory phenotype in monocytes (Bekker et al., 2014), was also differentially regulated upon BCG vaccination (Table S3).

RNA sequencing has also been performed on the same samples, but as expected and as shown before (Novakovic et al., 2016; Saeed et al., 2014), no major differences were found. This shows that trained monocytes are epigenetically primed to respond (transcriptionally) differently to a secondary stimulus (e.g., ex vivo stimulation), but that in resting state they do not display a changed transcriptional program.

Epigenetic Reprogramming Is Accompanied by Functional Changes

In line with our previous finding of BCG-induced functional changes in monocytes (Arts et al., 2016; Cheng et al., 2016), we demonstrate that genes involved in the PI3K/AKT/mTOR pathway are already marked at epigenetic level. This pathway has a crucial role for the increased cytokine production capacity during induction of trained immunity (Arts et al., 2016; Cheng et al., 2016), and these epigenetic changes upon BCG vaccination were indeed accompanied by enhanced ex vivo cytokine responses to unrelated pathogens, as shown by increased cytokine production capacity 1 month after BCG vaccination (Figures 2A, 2B, and S2), which was not the result of differences in monocyte subpopulations or total monocyte number (Figure S3A). Heterologous T cell responses were moderately increased after BCG vaccination (Figure S2). Induction of monocyte-derived cytokine production (used here as a readout of trained immunity) varied between individuals, with unsupervised cluster analysis of increased cytokine production 1 month after BCG vaccination clearly showing a cluster of innate cytokines and a second cluster of T helper 1/Th17 lymphocyte cytokines. Within the innate cytokine cluster, the induction of IL-1β and IL-6 production was highly correlated (Figure 2C).

BCG Vaccination Lowers Yellow Fever Viremia

To examine the clinical significance of the observed epigenetic and functional effects of BCG, we used the live-attenuated...
**Figure 2. BCG Induces Trained Immunity In Vivo**

(A) Healthy volunteers randomly received BCG or placebo vaccination. Before vaccination and 1 month later, blood was drawn and PBMCs were isolated and restimulated *ex vivo*.

(B) Fold increases (compared to baseline) of IL-1β, TNFα, and IL-6 production to LPS, *M. tuberculosis* (MTB), and *C. albicans* are shown (mean ± SEM, n = 15 per group, *p < 0.05 BCG versus placebo, **p < 0.01 mean versus 1, ***p < 0.01 mean versus 1, fold increase baseline versus 1 month, Mann-Whitney U test).

(C) Unsupervised clustering analysis performed on Spearman's correlations of fold induction of cytokines as presented in (B), IL-1β, TNFα, IL-6, and IL10 were determined after 24 hr and IL-17, IL-22, and IFNγ after 7 day *ex vivo* incubation with LPS, *M. tuberculosis* (MTB), *S. aureus*, or *C. albicans*. 
YFV as a model for a viral human infection. YFV viremia, determined by RT-PCR, peaked on day 5 after vaccination, as previously reported by others (Edupuganti et al., 2013) (Figures 3A, 3B, and S3B). Subjects who had been BCG vaccinated 1 month prior to yellow fever vaccination showed significantly lower viremia compared to subjects who had received placebo vaccination (Figure 3B, higher CT values, thus lower viremia, for BCG-vaccinated volunteers). Lower circulating virus concentrations in BCG-vaccinated volunteers were also reflected by lower concentration of circulating cytokines (Figure 3C). Circulating IL-1β concentrations before and after vaccination were below detection limit in almost all samples (mean ± SEM, n = 15 per group, *p < 0.05, **p < 0.01, Mann-Whitney U test).

Importantly, when yellow fever-neutralizing antibodies were measured at 3 months post-vaccination, no significant differences were found between viremia and concentrations of the Th17 cytokines IL-17 and IL-22 (Figure 3D). This is remarkable, as we and others have found an induction of CD8+ and polyfunctional CD4+ responses after BCG vaccination (Figure S2) (Boer et al., 2015; Kleinnijenhuis et al., 2012). Concentrations of yellow fever-neutralizing antibody titers also did not correlate with induction of cytokines (neither innate nor adaptive) (Figure 4D).

Epigenetic Differences Influence Yellow Fever Viremia

Apart from the correlation with cytokine induction, correlation of epigenetic changes induced by BCG and yellow fever viremia were also determined. In order to do so, volunteers presented in Figure 1 were divided into a group of responders to BCG vaccination (R, maximum yellow fever viremia CT > 36) and non-responders (NR, CT < 36). Pre-existing H3K27Ac epigenetic differences (at baseline, before BCG vaccination) at the gene region level were determined between these two groups of volunteers, suggestive of the pathways important for the post-vaccination response. Interestingly, the top-ranked genomic region in this analysis was 7.6 kb upstream of the gene coding for NOD2 (FC = 6.3, adjusted p value = 2.42 × 10−8), the innate immune receptor recognizing muramyl dipeptide: an earlier study demonstrated that monocytes isolated from individuals with NOD2 mutations leading to a defective receptor cannot be trained in vitro with BCG (Arts et al., 2015; Kleinnijenhuis et al., 2012) (Figures 4A and S4A). In contrast, increased IL-1β production capacity after BCG vaccination strongly predicted lower viremia after subsequent yellow fever infection (Figures 4A and 4B). Among the other cytokines, induction of IL-10 upon stimulation with Candida albicans also displayed a negative correlation with viremia (Figures 4A, 4B, and S4A). Interestingly, viremia did not correlate with induction of specific cellular responses to YFV by BCG as measured by IFNγ production by PBMCs (Figures 4C and S4B). In addition, no correlation was found between viremia and concentrations of the Th17 cytokines IL-17 and IL-22 (Figure S4A). This is remarkable, as we and others have found an induction of CD8+ and polyfunctional CD4+ responses after BCG vaccination (Figure S2) (Boer et al., 2015; Kleinnijenhuis et al., 2012). Concentrations of yellow fever-neutralizing antibody titers also did not correlate with induction of cytokines (neither innate nor adaptive) (Figure 4D).

Non-specific IL-1β Production Increase after BCG Vaccination Is a Correlate of Protection against Yellow Fever Viremia

We next determined whether the induction of ex vivo cytokine responses associated with trained immunity, as noted earlier, correlated with yellow fever viremia. Post-vaccination increases in TNFα and IL-6 production did not correlate with viremia (Figures 4A and S4A). In contrast, increased IL-1β production capacity after BCG vaccination strongly predicted lower viremia after subsequent yellow fever infection (Figures 4A and 4B). Among the other cytokines, induction of IL-10 upon stimulation with Candida albicans also displayed a negative correlation with viremia (Figures 4A, 4B, and S4A). Interestingly, viremia did not correlate with induction of specific cellular responses to YFV by BCG as measured by IFNγ production by PBMCs (Figure S3C).

Cell Host & Microbe 23, 89–100, January 10, 2018
Furthermore, pathway analysis of H3K27ac profiles between R and NR reveals several interesting results. Once more, RNA-seq analysis did not show a clear pattern, as expected, as cells were not re-stimulated prior to analysis (Figure 5C). Among the main differentially regulated pathways at the epigenetic (but not RNA) level was “TB latent infection,” which is in line with the BCG vaccination, as well as general immunological pathways such as “Immune Response” and “Response to Cytokine Stimulus” (Figure S5A), showing the epigenetic correlates of protection to yellow fever viremia.

Genetic Polymorphisms in Genes of IL-1β Pathway Modulate Trained Immunity Response

The role of IL-1β as a trained immunity correlate of protection against yellow fever viremia was supported by additional genetic and immunological validation studies. First, we examined the effect of genetic variations in IL1B on BCG-induced trained immunity cytokine responses in the 200FG cohort of healthy volunteers (Li et al., 2016). Strikingly, the cytokine responses indicative of trained immunity that were induced by BCG were modulated by a known polymorphism located in the promoter region of the gene encoding IL-1β (IL1B; rs16944) (Figure 6A). The presence of two copies of the A allele of rs16944 was associated with significantly impaired cytokine production associated with trained immunity responses. Interestingly, in vitro studies have shown that the IL1B rs16944 A allele is associated with decreased IL-1β production (Wen et al., 2006; Wójtowicz et al., 2015). In line with these findings, we demonstrated reduced mRNA expression of IL-1β in individuals having the AA genotype compared to individuals who inherited the GG genotype (Figure S5B). As further support for the role for IL-1β in BCG-induced trained immunity, polymorphisms in several additional IL-1 family genes, encoding IL-1 and IL-18 receptors as well as the inflammasome component PYCARD/ASC, showed a strong impact on the induction of cytokines associated with trained immunity (Figure 6B). In contrast, polymorphisms in the gene encoding TNFα did not modulate in vitro trained immunity responses, and only one polymorphism in IL6 was found to weakly affect training (data not shown).
Epigenetic Changes Mediate IL-1β-Induced Trained Immunity

To obtain further insight into the role of IL-1β in mediating trained immunity responses, we next assessed whether IL-1β itself can induce trained immunity in vitro. Using the previously described in vitro model of trained immunity (Bekkering et al., 2016; Klein-nijenhuis et al., 2012), priming of monocytes with IL-1β (1–10 ng/mL) for 24 hr (Figure 6C) enhanced production of the pro-inflammatory cytokines IL-6 and TNFα upon LPS restimulation on day 6 (Figure 6D). We also observed enhanced IL-8 production by monocytes that were trained with IL-1β or BCG and were restimulated with YFV. mRNA expression analysis of IL-8 demonstrated an enhanced upregulation of IL-8 in both BCG and IL-1β trained monocytes compared to control (Figure 6E). Restimulation with YFV on day 6 did not lead to IL-6 or TNFα production (data not shown). Pre-treatment with the histone methyltransferase inhibitor MTA (5′-deoxy-5′-methylthio-adenosine) abrogated the IL-1β-induced trained immunity response, suggesting that the in vitro training effect of IL-1β is mediated via epigenetic reprogramming of monocytes (Figure 6F). This was confirmed by IL-1β-mediated induction of epigenetic changes 6 days after IL-1β treatment in promoter regions of TNFA, IL6, and IL1B, with increased trimethylation of lysine 4 at histone 3 (H3K4me3; Figure 6H), a repressor mark. The increase of H3K4me3 and the decrease of H3K9me3 induced by IL-1β was most pronounced at the promoter of IL1B.

DISCUSSION

Recent studies demonstrated that functional adaptation of innate immune cells after an infection or vaccination, which is induced through epigenetic reprogramming, is responsible for
a de facto innate immune memory, also termed trained immunity (Netea et al., 2016). BCG vaccination has long been known to be accompanied by lower mortality in vaccinated children, an effect that cannot be fully ascribed to protection against tuberculosis, but that is probably due to protection against neonatal sepsis and respiratory tract infections. Although it has been reported that this heterologous protection is due at least in part to induction of trained immunity (Kleinnijenhuis et al., 2012), no comprehensive assessment of the epigenetic programs induced by BCG has been done until now. Also, evidence for protective effects of BCG-induced trained immunity on unrelated infections in humans is outstanding.

In this study, we describe the epigenetic changes induced at a genome scale by BCG in human monocytes. We chose to study the H3K27ac histone mark because it is associated with an “active” chromatin state at both gene promoters and enhancers. Moreover, we previously showed a strong correlation between H3K27ac and H3K4me3 changes during trained immunity, with H3K27ac being the most dynamic mark (Saeed et al., 2014). Among the genes displaying increased H3K27ac, we identified enrichment in genes encoding for proteins involved in cellular signaling as well as inflammation: cytokines and chemokines, the EGFR and VEGF pathways. In addition, the PI3K/AKT pathway is also shown to be upregulated, and this is supported by the recent studies demonstrating its involvement in the induction of trained immunity by both BCG and β-glucan (Arts et al., 2016; Cheng et al., 2014). The epigenetic profile induced by BCG shows close similarities to the trained immunity induced by β-glucan in vitro (Saeed et al., 2014), suggesting there is a core trained immunity response induced by different stimuli.

The epigenetic reprogramming of monocytes induced by BCG vaccination is accompanied by significantly altered responses of innate immune cells. This process is clearly illustrated here by higher pro-inflammatory cytokine production (TNFα, IL-1β, IL-6) of PBMCs from BCG-vaccinated volunteers, compared to placebo-treated individuals. We have in this case opted for PBMC stimulation (and not highly purified monocytes) to mimic as closely as possible the in vivo clinical situation. In addition, while the epigenetic changes observed in highly purified monocytes are indicative of the induction of trained immunity programs by BCG vaccination, the functional consequences measured in PBMCs may be also influenced by the presence of lymphocytes. Differences in cytokine production after BCG vaccination were seen in earlier studies both in children (Jensen et al., 2013) and in adults (Kleinnijenhuis et al., 2012). The amplitude of the cytokine responses indicative of trained immunity induction in the current study is somewhat less strong compared to previous studies, probably due to BCG batch differences (Biering-Sørensen et al., 2015).

Unequivocally, demonstration of a correlation between the induction of trained immunity and protection against a controlled infection in humans has been outstanding. Our proof-of-principle study showed that BCG vaccination protects against a subsequent, non-related viral infection in a human controlled model of YFV infection. This model has the advantage of the use of a live virus, which has no deleterious effects on the host and which can be quantitatively monitored by PCR. The demonstration of a significantly lower peak of viremia in BCG-vaccinated individuals compared to individuals injected with placebo clearly demonstrates the capacity of BCG to protect against non-related infections in humans. The lower viremia was also accompanied by lower circulating inflammatory mediators in the BCG-vaccinated individuals. This result is expected, as the high cytokine production capacity upon BCG vaccination will lead to a rapid local antimicrobial response and subsequent elimination of the pathogen, thereby preventing a systemic reaction and high levels of circulating cytokines (Netea et al., 2003; van der Poll et al., 2017). Importantly, despite the lower virus load, BCG vaccination did not affect generation of protective anti-yellow fever antibodies and did not affect the specific effect of YFV. This suggests that BCG might improve the antigen-presenting capacity and adaptive responses, in line with a study showing beneficial effects on the response to influenza vaccine (Leentjens et al., 2015). The observed effects that are indicative of trained immunity induction are clinically very relevant, as epidemiological studies have shown that BCG vaccination results in lower all-cause mortality in the first month after birth (Aaby et al., 2011; Roth et al., 2004). However, long-term studies with broader analysis of monocyte function are warranted in order to determine the duration of the BCG effect. Importantly, significant differences in epigenetic markers were apparent on monocytes from BCG responders (with low yellow fever viremia) and BCG vaccinated non-responders.

Figure 6. The Role of IL-1β for Trained Immunity

(A) Genetic variations in IL-1β were assessed in DNA samples from 98 healthy volunteers from the 200FG cohort by a genome-wide Illumina Infinium SNP array. Monocytes were isolated and stimulated in vitro with culture medium (negative control) or BCG (10 μg/mL) for 24 hr. On day 6, cells were restimulated with culture medium or LPS (10 ng/mL). After 24 hr, supernatants were taken and cytokine concentrations were assessed using ELISA. Medium-restimulated cells did not produce detectable cytokine production. A SNP in IL-1β (IL1B; rs16944) was found to affect the trained immunity response induced by BCG (mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, Mann-Whitney U test).

(B) Additional genetic analysis in genes of the IL-1β pathway identify polymorphisms in the IL-1 and IL-18 receptors, as well as the inflammasome component PYCARD/ASC, that significantly modulate BCG-induced trained immunity.

(C) Schematic outline of the in vitro training experiments. Human monocytes were primed for 24 hr with culture medium or different concentrations of IL-1β. On day 6, cells were restimulated for 24 hr with LPS, and levels of IL-8 and TNFα were assessed (mean ± SEM, n = 7, *p < 0.05).

(D) Human monocytes were primed for 24 hr with culture medium or different concentrations of IL-1β. On day 6, cells were restimulated for 24 hr with LPS, and levels of IL-6 and TNFα were assessed (mean ± SEM, n = 7, *p < 0.05).

(E) Human monocytes were incubated with either culture medium, IL-1β (10 ng/mL), or BCG (5 μg/mL). At day 6, cells were restimulated with YFV (1,000 IU/mL). Concentrations of IL-8 in the supernatants were measured after 24 hr (mean ± SEM, n = 6), and mRNA expression of IL-8 was determined after 4 hr restimulation (mean ± SEM, n = 3 in duplo, *p < 0.05, Wilcoxon signed-rank test).

(F) Monocytes were stimulated for 24 hr with culture medium or IL-1β (100 ng/mL) in the presence or absence of MTA (1 mM). On day 6, after restimulation with LPS for 24 hr, IL-6 and TNFα were measured in the supernatants (mean ± SEM, n = 7, *p < 0.05, Wilcoxon signed-rank test).

(G and H) Human monocytes were stimulated for 24 hr with culture medium or IL-1β (100 ng/mL). Chromatin was fixed on day 6 and ChiP-qPCR was performed. H3K4me3 and H3K9me3 were determined at promoters of IL6, TNFA, and IL1B (mean ± SEM, n = 8, *p < 0.05, Wilcoxon signed-rank test).
non-responders (with higher viremia), H3K27ac at the level of the NOD2 receptor (which is essential for the induction of BCG-induced trained immunity [Kleinnijenhuis et al., 2012]) correlated best with response to BCG. Additional immune pathways related to cytokine production and innate immune responses were shown to be of importance.

One of the most remarkable observations was made when the correlates of protection against viremia were investigated. It was previously suggested that development of a scar after BCG vaccination could be used as a marker for non-specific effects and childhood survival (Garly et al., 2003; Roth et al., 2005). However, all BCG-vaccinated volunteers developed a scar with a comparable size (0.5–0.7 cm), and we observed no correlation of this with protection. In addition, the fold change of heterologous T cell responses (IFNγ, IL-17, and IL-22 production) upon BCG vaccination did not show any correlation with the YFV viremia. In contrast, the post-BCG fold increase of IL-1β production strongly correlated with lower viremia after YFV administration, while production of other monocyte-derived cytokines showed less correlation. This suggests that induction of IL-1β production stimulated by non-related pathogens, which is an indicator of trained immunity responses, rather than adaptive cellular responses as assessed by IFNγ production induced by specific stimuli, is responsible for the protection induced by BCG against the viral infection.

The fact that the increase in the capacity of innate immune cells to release IL-1β is the stronger correlate of protection suggests that this cytokine is a crucial component of trained immunity. This finding is highly relevant due to the direct protective effect of higher IL-1β levels in viral infections (Azuma et al., 1992; Iida et al., 1989; Sergerie et al., 2007), although other mechanisms are possible as well. The role of IL-1β is supported by complementary genetic and immunological studies. By studying in vitro training of monocytes induced by BCG in cells isolated from healthy volunteers of the 200FG cohort (Li et al., 2016), we demonstrate that genetic polymorphisms in the gene encoding for IL-1β, but also other genes of the IL-1 pathway such as the inflammasome component ASC/PYCARD and genes encoding for the IL-1 and IL-18 receptors, are associated with the magnitude of the individual trained immunity response induced by BCG. In follow-up experiments, we found that IL-1β itself can induce trained immunity, and that this effect is accompanied by epigenetic changes at the level of histone methylation (H3K4me3 and H3K9me3). This may explain earlier studies that have shown that administration of one dose of IL-1β to mice before infection can protect against lethal bacterial and fungal sepsis (van der Meer et al., 1988). In addition, IL-1β is well known to exert strong effects on myelopoiesis (Dinarello, 2002), and one may hypothesize that IL-1β represents the endogenous mediator between the peripheral stimulation of monocytes and macrophages by BCG and long-term functional reprogramming at the level of bone marrow progenitors. Indeed, accompanying studies from the International Trained Immunity Consortium (INTRIM) in an upcoming issue of Cell demonstrate that effects at the level of myeloid cell progenitors are crucial for the induction of trained immunity by β-glucan (Mitroulis et al., 2018), BCG (Kauffmann et al., 2018), and Western-type diet (Christ et al., 2018) and identify IL-1β and the inflammasome pathway as key mediators of this process (Mitroulis et al., 2018; Christ et al., 2018). Mitroulis et al. show that the adaptations in hematopoietic stem and progenitor cells (HSPCs) are associated with an increase in IL-1β (and not other cytokines) in the bone marrow fluid, while inhibition of IL-1β prevented the β-glucan-dependent expansion of HSPCs and the effects on myeloid cell progenitors. Similarly, Christ et al. demonstrate that a Western-type diet is able to induce trained immunity in mice, and IL-1β plays an important role in this effect. Thus, Western-type diet did not induce trained immunity and myeloid progenitor reprogramming in NLRP3 knockout mice that have defects in IL-1β processing. Similarly, genetic analysis revealed that polymorphisms in NLRP3 influenced oxLDL-induced trained immunity in human cells.

As dysregulated IL-1β production plays a pivotal role in the etiology of many autoinflammatory diseases, the capacity of IL-1β to induce trained immunity may represent a central event in the pathophysiology of these disorders. This needs further investigation, as it may represent a therapeutic target for these diseases. Indeed, the accompanying study by Bekkering et al. of the INTRIM Consortium shows a dysregulated trained immunity phenotype in monocytes isolated from patients with hyper IgD syndrome (Bekkering et al., 2018), a well-known autoinflammatory syndrome.

In conclusion, in the present study we report the broad epigenetic program induced by BCG vaccination in humans, which results in increased activation of circulating monocytes. Furthermore, we show that BCG vaccination can protect against a non-related viral infection in an experimental model of human infection and report that IL-1β-mediated responses, which are indicative of the induction of trained immunity, are the most reliable correlate of this protection. Additional genetic and immunological validation studies demonstrate that IL-1 pathway is crucial for an efficient induction of trained immunity in humans, and this may have important implications for both vaccination and the pathophysiology of autoinflammatory diseases.

STAR METHODS
Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
- **METHOD DETAILS**
  - PBMC and Monocyte Isolation and Stimulation
  - In Vitro Training Experiments
  - Cytokine Measurements
  - mRNA Extraction and RT-PCR
  - In Vitro Assessment of Specific Histone Marks
  - In Vivo Assessment of Genome-Wide Epigenetic Profiles
  - Library Preparation for Sequencing
  - Yellow Fever RT-qPCR and Antibody Titers
  - Genetic Analysis
  - ChIP-Seq Analysis
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **DATA AND SOFTWARE AVAILABILITY**
  - Data Resources
SUPPLEMENTAL INFORMATION

Supplemental Information includes five figures and four tables and can be found with this article online at https://doi.org/10.1016/j.chom.2017.12.010.

ACKNOWLEDGMENTS

M.G.N. was supported by an ERC Consolidation Grant (310372) and a Spinoza grant from the Netherlands Organisation for Scientific Research (NWO). M.O. was supported by a VENI grant 016.176.006 from the Netherlands Organisation for Scientific Research (NWO). B.N. was supported by an NHMRC (Australia) CJ Martin Fellowship. C.S.B. and P.A. were supported by the Danish National Research Foundation (DNRF108).

AUTHOR CONTRIBUTIONS


DECLARATION OF INTERESTS

The authors declare no conflict of interest.

REFERENCES


## STAR METHODS

### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabbit polyclonal anti-H3K4me3</td>
<td>Diagenode</td>
<td>pab-003-050</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-H3K27Ac</td>
<td>Diagenode</td>
<td>pab-196-050, C15410196</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-H3K9me3</td>
<td>Diagenode</td>
<td>pab-193-050, C15410193</td>
</tr>
</tbody>
</table>

### Antibodies

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabbit polyclonal anti-H3K4me3</td>
<td>Diagenode</td>
<td>pab-003-050</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-H3K27Ac</td>
<td>Diagenode</td>
<td>pab-196-050, C15410196</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-H3K9me3</td>
<td>Diagenode</td>
<td>pab-193-050, C15410193</td>
</tr>
</tbody>
</table>

### Chemicals, Peptides, and Recombinant Proteins

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacille Calmette-Guérin Vaccin (BCG)</td>
<td>Statens Serum Institute, Copenhagen</td>
<td>2016-04</td>
</tr>
<tr>
<td>Yellow fever vaccine</td>
<td>Sanofi Pasteur</td>
<td>Stamaril</td>
</tr>
<tr>
<td>Lipopolysaccharide</td>
<td>Sigma-Aldrich</td>
<td>From E. coli serotype 055:B5, L2880</td>
</tr>
<tr>
<td>Mycobacterium tuberculosis</td>
<td>Gift</td>
<td>H27Rv</td>
</tr>
<tr>
<td>Candida albicans</td>
<td>Gift</td>
<td>UC820</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>Clinical isolate</td>
<td></td>
</tr>
<tr>
<td>Recombinant human Interleukin-1 α</td>
<td>R&amp;D Systems</td>
<td>201-LB-005</td>
</tr>
<tr>
<td>5′-Deoxy-5′-(methylthio) adenosine (MTA)</td>
<td>Sigma-Aldrich</td>
<td>D5011</td>
</tr>
<tr>
<td>Percoll</td>
<td>Sigma-Aldrich</td>
<td>P1644</td>
</tr>
<tr>
<td>Ficoll-Paque</td>
<td>GE Healthcare</td>
<td>17-1440-03</td>
</tr>
<tr>
<td>Roswell Park Memorial Institute medium (RPMI)</td>
<td>Invitrogen</td>
<td>22406031</td>
</tr>
<tr>
<td>Bovine Serum Albumin (BSA)</td>
<td>Sigma-Aldrich</td>
<td>A7030</td>
</tr>
<tr>
<td>CD14+ beads</td>
<td>MACS Miltenyi</td>
<td>130-050-201</td>
</tr>
<tr>
<td>iScript reverse transcriptase</td>
<td>Bio-Rad</td>
<td>1708840</td>
</tr>
<tr>
<td>TRIZol reagent</td>
<td>Life Technologies</td>
<td>15596018</td>
</tr>
<tr>
<td>SYBR Green</td>
<td>Applied Biosciences</td>
<td>4368708</td>
</tr>
<tr>
<td>16% Formaldehyde</td>
<td>Fisher Scientific</td>
<td>28908, 11835835</td>
</tr>
<tr>
<td>Protein A/G Magnetic beads</td>
<td>Diagenode</td>
<td>C03010021-150</td>
</tr>
</tbody>
</table>

### Critical Commercial Assays

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Illumina Infinium SNP array</td>
<td>Illumina</td>
<td></td>
</tr>
<tr>
<td>Human IL-1α ELISA</td>
<td>R&amp;D Systems</td>
<td>DY201</td>
</tr>
<tr>
<td>Human TNFα ELISA</td>
<td>R&amp;D Systems</td>
<td>DY210</td>
</tr>
<tr>
<td>Human IL-17 ELISA</td>
<td>R&amp;D Systems</td>
<td>D1700</td>
</tr>
<tr>
<td>Human IL-22 ELISA</td>
<td>R&amp;D Systems</td>
<td>D2200</td>
</tr>
<tr>
<td>Human IL-6 ELISA</td>
<td>Sanquin</td>
<td>M1916</td>
</tr>
<tr>
<td>Human IL-8 ELISA</td>
<td>Sanquin</td>
<td>M1918</td>
</tr>
<tr>
<td>Human IFNγ ELISA</td>
<td>Sanquin</td>
<td>M1933</td>
</tr>
<tr>
<td>Milliplex human TH17 panel</td>
<td>Merck</td>
<td>HTH17MAG-14K</td>
</tr>
<tr>
<td>Bradford Concentration Assay</td>
<td>Thermo Fisher Scientific</td>
<td>23246</td>
</tr>
<tr>
<td>iScript cDNA Synthesis Kit</td>
<td>Bio-Rad</td>
<td>1708891</td>
</tr>
<tr>
<td>KAPA library preparation kit</td>
<td>Kapa Biosystems</td>
<td>KK8400</td>
</tr>
<tr>
<td>riboZero gold rRNA removal kit</td>
<td>Illumina</td>
<td>MRZG12324</td>
</tr>
<tr>
<td>Nextera DNA Library Prep Kit</td>
<td>Illumina</td>
<td>FC-121-1031</td>
</tr>
<tr>
<td>TruSeq SBS KIT v3 - HS (60 cycles)</td>
<td>Illumina</td>
<td>FC-401-3002</td>
</tr>
<tr>
<td>NextSeq 500/550 High Output v2 kit (75 cycles)</td>
<td>Illumina</td>
<td>FC-404-2005</td>
</tr>
<tr>
<td>NEBNext High-Fidelity 2 x PCR Master Mix</td>
<td>New England Biolabs</td>
<td>M0541</td>
</tr>
<tr>
<td>iQ SYBR Green Supermix</td>
<td>Bio-Rad</td>
<td>1708880</td>
</tr>
<tr>
<td>100 × SYBR Green I Nucleic Acid Gel Stain</td>
<td>Thermo Fisher Scientific</td>
<td>S7563</td>
</tr>
<tr>
<td>SPRiselect reagent kit</td>
<td>Beckman Coulter</td>
<td>B23218</td>
</tr>
</tbody>
</table>

(Continued on next page)
## CONTINUATION

### REAGENT or RESOURCE | SOURCE | IDENTIFIER
--- | --- | ---
E-Gel SizeSelect Agarose Gels, 2% | Thermo Fisher Scientific | G661002
DNTP set 100 mM | Life Technologies | 10297-018
dUTP 100 mM | Promega | U119A
Glycogen (20 mg/mL) | Life Technologies | 10814-010
Random Hexamer primers | Sigma-Aldrich | 11034731001
Second Strand Buffer | Life Technologies | 10812-014
Superscript III Reverse Transcriptase | Life Technologies | 18080-044
DNA polymerase I, E. coli | New England Biolabs | M0209S
USER enzyme | New England Biolabs | M5505L
E. coli Ligase | New England Biolabs | M0205L
Rnasin Plus Rnase Inhibitor | Promega | N2615
Ribonuclease H | Life Technologies | AM2293
T4 DNA polymerase | New England Biolabs | M0203L
Sodium Acetate (3M) | Life Technologies | AM9740
DNase I | QIAGEN | 79254
Qubit RNA HS assay kit | Life Technologies | Q32852
Ribozero Gold Kit | Illumina | MRZG12324
Rneasy Mini Kit | QIAGEN | 74106

**Deposited Data**

| REAGENT or RESOURCE | SOURCE |
--- | --- |
BCG in vivo trained monocytes ChIP-seq and RNA-seq data | This paper |

| EXPERIMENTAL MODEL or STRAIN | SOURCE |
--- | --- |
Human genome assembly hg19 | NCBI |
200FG cohort (Human Functional Genomics project) | http://www.humanfunctionalgenomics.org |

| OLIGONUCLEOTIDES | SOURCE |
--- | --- |
Primers for qPCR | Table S1 |

| SOFTWARE | SOURCE |
--- | --- |
Image Lab | Bio-Rad |
CXP analysis software v2.2 | Beckman Coulter |
GraphPad Prism | Graphpad Software |
| | https://www.graphpad.com |
MMSEQ | Turro et al., 2011 |
| | https://github.com/etouro/mmseq |
DEseq | Anders and Huber, 2010 |
Bwa | Li and Durbin, 2009 |
| | http://bio-bwa.sourceforge.net/ |
Samtools and Bamtools | Barnett et al., 2011; Li et al., 2009 |
MACS2 | Zhang et al., 2008 |
| | http://github.com/taoliu/MACS/ |
HOMER | Heinz et al., 2010 |
| | http://homer.salk.edu/homer/motif/ |
DAVID | Huang et al., 2009 |
| | https://david.ncifcrf.gov/ |

**CONTACT FOR REAGENT AND RESOURCE SHARING**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Mihai Netea at the Radboud University Medical Center, Nijmegen, the Netherlands (mihai.netea@radboudumc.nl).
EXPERIMENTAL MODEL AND SUBJECT DETAILS

Between February and November of 2015, we randomly assigned 30 healthy Dutch male subjects (age: 19-37 years) to receive either BCG (SSI, Denmark) or placebo (the diluent used to dissolve BCG) in a double-blind fashion. Volunteers were BCG naive and had not lived in a tuberculosis endemic area. One month after placebo or BCG vaccination, all volunteers received a single dose of YFV (Stamaril, Sanofi Pasteur). Blood was drawn before BCG/placebo and yellow fever vaccination, and 3, 5, 6, 14, and 90 days after yellow fever vaccination. One of the volunteers in the BCG group already had a protective yellow fever titer before yellow fever vaccination; this volunteer was excluded from yellow fever-related analyses. The study was approved by the Arnhem-Nijmegen Medical Ethical Committee, NL50160.092.24. Inclusion of volunteers and experiments were conducted according to the principles expressed in the Declaration of Helsinki. All volunteers gave written informed consent before any material was taken.

METHOD DETAILS

PBMC and Monocyte Isolation and Stimulation

Isolation and stimulation was performed as described before (Kleinnijenhuis et al., 2014; Kleinnijenhuis et al., 2012). Briefly, PBMCs were isolated by density centrifugation of Ficoll-Paque (GE healthcare, UK). Cells were washed twice in PBS and resuspended in Isolation and stimulation was performed as described before (Kleinnijenhuis et al., 2014; Kleinnijenhuis et al., 2012). Briefly, PBMCs were washed twice in PBS and resuspended in RPMI culture medium (Roswell Park Memorial Institute medium; Invitrogen, CA, USA) supplemented with 50 μg/mL gentamicin, 2 mM Glutamax (GIBCO), and 1 mM pyruvate (GIBCO) and diluted to a concentration of 5 x 10^5/mL. 100 μL/well was added to 96-well plates and cells were incubated for 24 hr or 7 days with RPMI, sonicated Mycobacterium tuberculosis H37Rv (5 μg/mL), heat-killed Candida albicans (1 x 10^6/mL, strain UC820) or Staphylococcus aureus (1 x 10^6/mL clinical isolate). Supernatants were collected after 24 hr or 7 days and stored at −20°C. Monocyte isolation was performed after the PBMC isolation step, by MACS isolation with CD14 positive magnetic beads (MACS Miltenyi) according to the protocol of the manufacturer. Monocytes were fixed in 1% methanol-free formaldehyde and stored in PBS before sonication, after which chromatin was stored at −80°C.

In Vitro Training Experiments

Monocytes were sonicated and incubated at 37°C. After 1 hr, cells were washed once with 200 μL warm PBS to remove non-adherent cells. Subsequently, monocytes were incubated with culture medium only (negative control), or 1, or 10 ng/mL IL-1β (R&D Systems) for 24 hr. Cells were washed once with 200 μL warm PBS and incubated for 5 days in culture medium supplemented with 10% human pooled serum. The medium was changed once on day 3 of incubation. On day 6, cells were restimulated for 24 hr with culture medium, 10 ng/mL Escherichia coli LPS (serotype 055:B5, Sigma-Aldrich) or 1,000 IU/mL YFV (Stamaril, Sanofi Pasteur). Subsequently, supernatants were collected and stored at −20°C until cytokine concentrations were assessed. In inhibition experiments, cells were pre-incubated for 30 min with 1 mM of a methyltransferase inhibitor MTA (5'- deoxy-5'-methylthio-adenosine, Sigma) prior to adding the stimuli.

Cytokine Measurements

Cytokine measurements were performed in the supernatants using commercial ELISA kits from R&D Systems (TNFα, IL-1β, IL-6, IL-8, IL-17 and IL-22; Minneapolis, MN, USA) or Sanquin (IL-6, IFNγ; Amsterdam, the Netherlands). Circulating cytokines after yellow fever vaccination were determined in plasma. Ethylenediaminetetraacetic acid (EDTA) anticoagulated blood was centrifuged at 2000 x g at 4°C for 10 min immediately after withdrawal, and plasma was stored at −20°C until analysis. Concentrations of TNFα, IL-6, IL-8, IL-10, IL-1β, IL-1 receptor antagonist (IL-1Ra), IFNα, and IFNγ were measured in plasma using a Luminex assay according to the manufacturer’s instructions (Milliplex; Millpore, Billerica, MA, USA).

mRNA Extraction and RT-PCR

For measurement of IL-1β expression in individuals with a genetic variant in IL1B, 2 x 10^6 PMBCs were added to flat bottom 24-well plates (Corning, NY, USA) and cells were let to adhere for 1 hr at 37°C. Subsequently, cells were washed twice with warm PBS and incubated for 1 hr with culture medium only as a negative control or LPS (10 ng/mL). To determine mRNA expression of cytokines in training experiments, monocytes were isolated as described above and incubated with either culture medium, IL-1β (10 ng/mL), or BCG (5 μg/mL). At day 6, cells were restimulated with YFV (1,000 IU/mL) for 4 hr. After the indicated incubation times, mRNA was extracted by TRIzol (Life technologies), according to the manufacturer’s instructions. cDNA was synthesized with iScript reverse transcriptase (Invitrogen) and relative expression was measured using SYBR Green method (Invitrogen) on an Applied Biosciences Step-one PLUS qPCR machine. Primers are listed in Table S1.

In Vitro Assessment of Specific Histone Marks

Monocyte isolation was performed by density gradient centrifugation according to the procedure described above. Isolated cells were counted in a Coulter counter (Coulter Electronics) and adjusted to 1 x 10^6 cells/mL. A 10 mL volume was added into 10-cm Petri dishes (Corning) and cells were trained as described. On day 6, cells were harvested and fixed in 1% methanol-free formaldehyde. Fixed cell preparations were sonicated using a Diagenode Bioruptor Pico sonicator using 5 cycles of 30 s on, 30 s off and ChIP was performed using antibodies against H3K4me3 and H3K9me3 (Diagenode). A MinElute PCR purification Kit (QIAGEN) was used.
for DNA isolation. Afterward, qPCR analysis was performed using the SYBR Green method and samples were analyzed by a comparative Ct method. Primers can be found in Table S1.

**In Vivo Assessment of Genome-Wide Epigenetic Profiles**

For genome-wide chromatin assessment we chose the histone 3 lysine 27 acetylation (H3K27ac) mark, which is generally associated with an “active” chromatin state at both gene promoters and distal (enhancer) regions, thereby extending the epigenetic profiles beyond promoter regions. Moreover, we previously showed a high correlation between H3K4me3 and H3K27ac change in response to exogenous stimuli, with H3K27ac being the more dynamic mark of the two (Saeed et al., 2014). Monocytes from BCG vaccinated volunteers were isolated and chromatin was crosslinked with 1% formaldehyde as described. Chromatin was sonicated and immunoprecipitated using an antibody for H3K27ac (Diagenode) as described previously (Novakovic et al., 2016).

**Library Preparation for Sequencing**

Illumina library preparation was performed using the Kapa Hyper Prep Kit (Kapa Biosystems). DNA was incubated with end repair and A-tailing buffer and enzyme and incubated first for 30 min at 20 °C and then for 30 min at 65 °C. Sample-specific NextFlex adapters were ligated by adding 30 μL ligation buffer, 10 Kapa DNA ligase, 5 μL diluted adaptor in a total volume of 110 μL and incubated for 15 min at 15 °C. Post-ligation cleanup was performed using Agencourt AMPure XP reagent at a bead:DNA ratio of 0.8:1 selecting sizes of > 150 bp. Libraries were amplified by adding 25 μL 2x KAPA HiFi Hotstart ReadyMix and 5 μL 10x Library Amplification Primer Mix and PCR, 10 cycles. Samples were purified using the QiAquick MinElute PCR purification kit and 300 bp fragments selected using E-gel. Correct size selection was confirmed by BioAnalyzer analysis. Paired-end sequencing was performed using the Illumina NextSeq 500 machine.

**Yellow Fever RT-qPCR and Antibody Titers**

RT-qPCR of YF-17D was performed at the department of Viroscience of the Erasmus Medical Center as described before (Wouthuizen-Bakker et al., 2017). Briefly, viral RNA was isolated using MagnaPure LC (Roche) and reverse transcribed (Taqman Reverse Transcription Reagents, Applied Biosystems International). cDNA synthesis was performed in a J Mini Gradient Thermal Cycler (BioRad, Netherlands) for real-time PCR, the following YF specific primers and probe were used YFV-1 (forward) 5'-AATCGAGTTGCTAGGCAATAAACAC-3', YFV-2 (reverse) 5'-TCCCTGAGCTTTACCAGA-3', YFV-P (probe) 5'-FAM-ATCGTTGAGCGATTACGAG-BHQ-3 (Drosten et al., 2002). Real-time qPCR was monitored on ABI Prism 7500 Seq. Detection System (Applied Biosystems International). Viremia is presented as relative viremia, by setting CT value 40 as 1, or by the formula Relative Viremia = 2 ^ (40 – Ct-value).

For YFV virus micro-neutralization tests 100 TCID50 of YFV vaccine strain 17D 204 (Stamaril, Sanofi-Pasteur) were incubated with two-fold serum dilutions (starting dilution serum 1:8) for 1 hr at 37 °C. Subsequently inoculum was allowed to bind to Vero cells for 1 hr at 37 °C, after which cells were incubated for 5 days at 37 °C. YFV infection was read out by cytopathic effect.

**Genetic Analysis**

For the genetic validation study, we assessed genetic variation in the genes of the IL-1 pathway in healthy individuals of Western European decent from the 200FG cohort (Li et al., 2016) by genome-wide Illumina Infinium SNP array. The genotype data were imputed and filtered using criterion of minor allele frequency ≥ 5% and other standard quality filters. The volunteers were between 23 and 73 years old, and consisted of 77% males and 23% females (Li et al., 2016). Monocytes were isolated as described earlier and stimulated in vitro with culture medium (negative control) or BCG (10 μg/mL) for 24 hr. On day 6, cells were restimulated with culture medium or LPS (10 ng/mL). After 24 hr, supernatants were collected and IL-6 and TNFα production were measured. Raw cytokine levels were first log-transformed then ratios to relative measures in culture medium (negative control) were computed. The ratio data were mapped to genotype data using a linear regression model with age and gender as covariates. The genetic variants located within the IL-1 family genes or in a ± 250 kb window were tested for genetic association with BCG-induced trained immunity.

**ChIP-sequencing Analysis**

ChIP-sequencing reads were aligned to human genome assembly hg19 (NCBI version 37) using bwa. Duplicate reads were removed after the alignment with the Picard tools and BAM files were first filtered to remove the reads with mapping quality less than 15, followed by fragment size modeling (https://code.google.com/archive/p/phantompeaktools/). MACS2 (https://github.com/taoliu/MACS2) was used to call the peaks. Data (H3K27ac reads/peak) were normalized using the R package DESeq2 and then pairwise comparisons were performed. Differential H3K27ac peaks were identified as those with fold change > 1.5, p value < 0.05 and reads/peak ≥ 15, between the baseline (-d28) and BCG vaccinated groups, similar to (Novakovic et al., 2016). Additionally, to identify possible donor-specific BCG responses, we identified H3K27ac peaks that showed a > 3 standard deviation change from mean level at baseline in any of the BCG vaccinated individuals, similar to (Saeed et al., 2014). H3K27ac peaks were assigned to the nearest gene within 1Mb and gene ontology analysis on dynamic enhancer clusters was performed using GREAT (McLean et al., 2010).

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Statistical parameters including the exact value of n, the definition of center, dispersion and precision measures (mean ± SEM), and statistical significance are reported in the figures and figure legends. Differences were analyzed using Wilcoxon signed-rank test or
Mann-Whitney U test where applicable. For cytokine production before and after BCG vaccination, fold increases (1 month after BCG divided by baseline cytokine production by PBMCs) are presented in order to increase clarity. The statistical analyses presented are performed on these ratios. The analyses did not show major differences with the raw data analysis. All calculations were performed in Graphpad prism 5 (CA, USA). p < 0.05 was considered statistically significant and in figures, asterisks denote statistical significance (*p < 0.05; **p < 0.01; ***p < 0.001. Data are shown as means ± SEM.

DATA AND SOFTWARE AVAILABILITY

Data Resources
Raw data files for the BCG in vivo trained monocytes ChIP sequencing and RNA sequencing analysis have been deposited in the NCBI Gene Expression Omnibus under accession number GEO: GSE104149.